

September 25, 2013

Mitsubishi Tanabe Pharma Corporation

Revision to 2Q Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2014

Osaka, Japan, September 25, 2013 --- Mitsubishi Tanabe Pharma Corporation (Head office: Chuo-ku, Osaka, President and Representative Director: Michihiro Tsuchiya) announced today a revision to the 2Q consolidated financial forecasts for the fiscal year ending March 31, 2014, which were announced on May 8, 2013.

1. Revised 2Q consolidated financial forecasts for the fiscal year ending March 31, 2014 (April 1, 2013 to September 30, 2013)

	Sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A)	Millions of yen 200,000	Millions of yen 30,000	Millions of yen 31,000	Millions of yen 19,000	Yen 33.87
Revised forecast (B)	200,000	30,000	31,000	26,000	46.35
Difference (B-A)	—	—	—	7,000	—
Percentage change (%)	—	—	—	36.8	—
(Reference) Results in the same period of the previous fiscal year	203,829	32,246	33,119	19,492	34.75

2. Reason for revision:

As a result of an arbitration award in a dispute with Janssen Biotech, Inc., which was announced on August 8, 2013, the Company recorded 11.0 billion yen as extraordinary income arising from overpayment of the supply price for Remicade attributable to previous years. Consequently, the Company has revised the net income forecast of the 2Q for fiscal year ending March 31, 2014 (April 1, 2013 to September 30, 2013). However, the Company has not changed the full year financial forecasts, which were announced on May 8, 2013.

Note: The above results forecasts reflect judgments and assumptions that are based on information available at the present point in time. For any of a number of reasons, actual results might differ materially from these forecasts.